| Description |
1 online resource (xiii, 304 pages) : illustrations |
| Series |
Current topics in microbiology and immunology ; v. 344 |
|
Current topics in microbiology and immunology ; v. 344.
|
| Contents |
Immune infiltration in human cancer : prognostic significance and disease control / Wolf H. Fridman [and others] -- Subversion and coercion : the art of redirecting tumor immune surveillance / John B. Mumm and Martin Oft -- STAT3 : a target to enhance antitumor immune response / Heehyoung Lee [and others] -- Biology and clinical observations of regulatory T cells in cancer immunology / Michele W. Teng [and others] -- Concepts and ways to amplify the antitumor immune response / Bent Rubin and Jean Edouard Gairin -- Angiogenesis and the tumor vasculature as antitumor immune modulators : the role of vascular endothelial growth factor and endothelin / Lana E. Kandalaft [and others] -- Adoptive cellular therapy / Stephen A. Grupp and Carl H. June -- Dendritic cell subsets as vectors and targets for improved cancer therapy / Karolina Palucka [and others] -- Identification of human idiotype-specific T cells in lymphoma and myeloma / Jinsheng Weng [and others] -- Modulation of CTLA-4 and GITR for Cancer Immunotherapy / Francesca Avogadri [and others] -- Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways / Shengdian Wang and Lieping Chen -- LAG-3 in cancer immunotherapy / Monica V. Goldberg and Charles G. Drake -- Immunologically active biomaterials for cancer therapy / Omar A. Ali and David J. Mooney -- Erratum : Identification of human idiotype-specific T cells in lymphoma and myeloma / Jinsheng Weng [and others] |
| Summary |
The recent FDA approval of Provenge® as the first therapeutic cancer vaccine together with the recent demonstration that Ipilimumab®, a monoclonal antibody that blocks the negative immune checkpoint cytotoxic T lymphocyte associated antigen-4, prolongs patient survival are major achievements that usher in a new era of cancer immunotherapy. These "(Bfirst-in-class" treatments reflect the substantive progress that basic and translational scientists have made towards understanding the mechanisms underlying protective tumor immunity in cancer patients Immunotherapies were first explored at the turn of the twentieth century, but the crafting of potent treatments required more detailed knowledge of how the immune system responds to cancer. Advances in genetic, cellular, and biochemical technologies have begun to yield this critical information, focusing attention on immune recognition, regulation, and escape. Indeed, the dynamic interplay of these processes in the tumor microenvironment is now recognized to play a decisive role in determining disease outcome. This volume highlights the rapid progress and breadth of research in cancer immunology, and provides a framework for anticipating many more clinical successes in cancer immunotherapy |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Print version record |
| Subject |
Cancer -- Immunological aspects.
|
|
Cancer -- Immunotherapy.
|
|
Immunotherapy.
|
|
Neoplasms -- immunology
|
|
Immunotherapy
|
|
Neoplasms -- therapy
|
|
HEALTH & FITNESS -- Diseases -- Cancer.
|
|
MEDICAL -- Oncology.
|
|
Immunotherapy
|
|
Cancer -- Immunological aspects
|
|
Cancer -- Immunotherapy
|
| Form |
Electronic book
|
| Author |
Dranoff, Glenn
|
| ISBN |
9783642141362 |
|
3642141366 |
|
3642141358 |
|
9783642141355 |
|
